Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients

References

• National Cancer Institute. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Myeloma [Internet]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html#incidence-mortality
   Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, . Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–2526.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L, Sureda A, . High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755–3759.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S, . High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131–3136.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM, . Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107–3114.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, van Rhee F, . Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176–185.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Gay F, Falco P, . Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800–807.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, . Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337–1341.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Bolejack V, Crowley J, . Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010;28:1599–1605.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Harrington D, Oken MM, . Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res 2002;62:715–720.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–3495.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, . Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28:4630–4634.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535–1548.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116: 354–365.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK, . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325–4336.
   PubMed Web of Science ®Google Scholar
• Sagaster V, Kaufmann H, Odelga V, . Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System. Eur J Haematol 2007;78:227–234.
   PubMed Web of Science ®Google Scholar
• Ross FM, Ibrahim AH, Vilain-Holmes A, . Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 2005;19:1634–1642.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Sonneveld P, . Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–157.
   PubMed Web of Science ®Google Scholar
• Klein U, Jauch A, Hielscher T, . Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 2010;117:2136–2144.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Zhan F, Burington BE, . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–2284.
   PubMed Web of Science ®Google Scholar
• Walker BA, Leone PE, Chiecchio L, . A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:e56–e65.
   PubMed Web of Science ®Google Scholar
• Anguiano A, Tuchman SA, Acharya C, . Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009;27:4197–4203.
   PubMed Web of Science ®Google Scholar